- Home
- ABUS
as 04-01-2025 4:00pm EST
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WARMINSTER |
| Market Cap: | 617.3M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 953.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.30 - $4.72 | Next Earning Date: | 03-27-2025 |
| Revenue: | $6,171,000 | Revenue Growth: | -65.98% |
| Revenue Growth (this year): | -14.13% | Revenue Growth (next year): | 61.99% |
Stock Insider Trading Activity of Arbutus Biopharma Corporation (ABUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Naftzger J. Christopher | ABUS | General Counsel and CCO | Feb 4 '25 | Sell | $3.28 | 11,333 | $37,206.24 | 86,244 | |
| Sims Karen | ABUS | Chief Medical Officer | Feb 4 '25 | Sell | $3.28 | 19,348 | $63,519.48 | 106,194 | |
| HASTINGS DAVID C | ABUS | Chief Financial Officer | Feb 4 '25 | Sell | $3.28 | 22,183 | $72,826.79 | 159,724 | |
| McElhaugh Michael J. | ABUS | Interim President & CEO | Feb 4 '25 | Sell | $3.28 | 23,790 | $78,102.57 | 1,481,003 |
Latest Arbutus Biopharma Corporation News
ABUS Breaking Stock News: Dive into ABUS Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
Zacks
2 days ago
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
BioPharma Dive
5 days ago
Novo gains Lexicon obesity drug; CRISPR COO to step down
Zacks
6 days ago
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
6 days ago
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Barrons.com
7 days ago
As Vaccine Skepticism Mounts, Moderna’s Business Grows More Precarious
MT Newswires
a month ago
Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement
GlobeNewswire
a month ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Compare ABUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABUS Arbutus Biopharma Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.